In the vicinity of BIO International Convention 2016, Fasken Martineau, Fonds FTQ, Montréal Invivo, To Health! and Teralys Capital are pleased to invite you to a panel of discussion on new trends and approaches in venture capital financing for SME in the life sciences sector.
Current themes of interest are:
- Trends and considerations in the life science innovation marketplace - past, present and future: through the eyes of a venture capital firm.
- Creating and financing disruptive innovation platform companies: lessons from California, their applicability in Canada/Quebec, and how to raise the bar on ambition among entrepreneurs, scientists and funds.
- Partnering early on vs. courting big pharma for later deals: pitfalls & success factors.
- Leading through examples: successful and not-so-successful stories- Do and Don'ts when interacting with a venture capital firm.
About the panelists:
Jerel Davis, Ph.D. - Versant Ventures
Jerel Davis is a Managing Director with Versant Ventures. Jerel has played a critical leadership role in a number of Versant's portfolio companies including Quanticel Pharmaceuticals, CRISPR Therapeutics, Northern Biologics, Turnstone Biologics, Inception 1-5 and IBD, as well as Versant's discovery engines Inception Sciences, Blueline, and Highline. Jerel has led Versant's execution of build-to-buy deals with Celgene, Roche, and Bayer and, in recent years, has established Versant's presence in Canada. Prior to joining Versant, Jerel was at McKinsey and Company as an Associate Principal advising biopharma, medical device, and molecular diagnostics companies. He has worked in a number of markets globally including the US, Canada, Europe, China, and Russia. Jerel was a post-doctoral researcher at Stanford University until 2005 and in research at Amgen in 1999.
Didier Leconte - Fonds de solidarité FTQ
Didier Leconte is Senior Director, Investments, Life Sciences at Fonds de solidarité FTQ. He and his group manage yearly investments of 50M$ in specialized funds, in biotechnology as companies well as mature companies. Over his career Didier has held various managing positions all related to innovation, from research to commercialization, and investment. He has been involved in multiple industries such as energy, electronic and telecommunication, before focusing in Life Sciences 10 years ago. Didier has an extensive expertise in technology transfer. In his previous role, he managed a seed investment fund dedicated to Québec based universities innovations. Didier holds a master in material engineering from Université Paris XIII, a MBA from UQAM as well as a certificate in Corporate Governance from the Collège des administrateurs de societiés, Université Laval.
Peter McWilliams - Sanderling Ventures
Peter McWilliams is a Managing Director of Sanderling Ventures with more than twenty years of experience in biomedical research and management. He has worked actively with multiple Sanderling portfolio companies in the role of Board Director, Chairman and Acting CEO. Prior to joining Sanderling, Dr. McWilliams worked at Genentech as a Product Manager in Oncology Commercial Development, where he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin. Prior to that he was an Associate with Booz & Co (now PwC) in San Francisco where he focused on consulting projects for major US and International life science companies. Prior to that he worked for Oxford Molecular, one of the early leaders in the field of rational drug design and bioinformatics. Dr. McWilliams received an M.B.A. from Columbia Business School, a Ph.D. and M.A. in Chemistry from Princeton University and a B.A. in Natural Sciences from Cambridge University
Done in partnership with Fasken Martineau, Montréal InVivo, Fonds FTQ, TO Health! and Teralys Capital and with the collaboration of Sherbrooke Innopole and Québec International.
Fasken Martineau is a leading international business law and litigation firm. With more than 700 lawyers, the firm has offices in Vancouver, Calgary, Toronto, Ottawa, Montréal, Québec City, London and Johannesburg. Fasken Martineau's Life Sciences group offer effective strategies from a wide range of perspectives. Our experience with the intellectual property, product liability, regulatory, tax, corporate and pricing aspects of life sciences allows us to anticipate and offer commercially effective solutions to all the issues your company will face. We work routinely with trusted legal specialists in pharmaceutical, biotechnology and medical devices in 47 countries on all continents. Fasken Martineau operates in English and French in civil law and common law jurisdictions worldwide.
TO Health! is an industry-led promotion cooperative focused on raising the profile of the Toronto region's Human Health & Sciences (HHS) cluster. TO Health! actively promotes and builds profile for the entire Toronto region HHS cluster by highlighting its strengths and successes and recognizing industry leaders within the cluster. TO Health! also assists groups with their own promotional outreach through TO Health! brand affiliation and resources, which can be used to powerfully present the region as a highly attractive place to live, work and invest.
Montréal InVivo is the brand name for the life sciences and health technologies (LSHT) cluster of the Montréal metropolitan area. The cluster comprises almost 600 organizations, including more than 150 research centres, four universities, 80 subsidiaries of world-class companies, and 40,000 people employed in the sector. The secretariat of Montréal InVivo is a non-profit economic development organization dedicated to the creation of wealth. By mobilizing the relevant actors, Montréal InVivo aims to ensure the sustainable development, long-term survival and international renown of the LSHT sector in Greater Montréal. Its activities are supported by funding from the Secrétariat à la région métropolitaine (ministère du Conseil exécutif), the Ministère de l'Économie, de l'Innovation et des Exportations, the Communauté métropolitaine de Montréal, the Canada Economic Development for Quebec Regions and private and institutional sector.
Teralys Capital is a private fund manager financing private venture capital funds investing in innovative businesses in information technologies, life sciences, and clean or industrial innovations. Our partner funds cover the entire investment spectrum from early stage start-ups to expansion, growth and technology buy-outs. With more than $1.6 billion in assets under management across two recent venture capital funds of funds and two additional legacy portfolios of funds, Teralys is the largest innovation-focused investor in Canada. Teralys has been supported since inception in 2009 by its many partners including the Caisse de dépôt et placement du Québec, the Fonds de solidarité FTQ and Investissement Québec. We also invest internationally, not only to benefit from favorable returns from established markets abroad, but also to support our leading technology funds and entrepreneurs here at home by extending their international reach and bringing back best practices from around the globe.
Created in 1983, the Fonds de solidarité FTQ is a development capital fund that calls upon the solidarity and savings of Quebecers to help fulfill its mission to contribute to Québec's economic growth by creating and protecting jobs through investments in small and medium-sized businesses in all spheres of activity. The Fonds also seeks to encourage Quebecers to save for retirement and to offer its over half a million shareholders-savers a reasonable return over and above the outstanding tax benefits they receive by purchasing Fonds shares. The largest development capital network in the province, the Fonds de solidarité FTQ was created on the initiative of the FTQ, Québec's largest central labour body. Through its governance and codes of ethics, the Fonds is a socially responsible investor committed to sustainable economic development where people come first. Aside from investing capital, the Fonds is committed to supporting the growth of its partner companies by offering value-added services such as economic training.